Potential drug-drug interactions of frequently prescribed medications in long COVID detected by two electronic databases.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
09
2022
accepted:
23
10
2023
medline:
20
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
epublish
Résumé
Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a wide range of acute and chronic complications including long COVID, a well-known chronic sequela. Long COVID often necessitates long-term treatment, which may lead to an increased potential for drug-drug interactions (DDIs). The objective of this study was to assess potential DDIs among frequently prescribed medications in long COVID by using two electronic databases. Sixty frequently prescribed agents were selected from Thailand's National List of Essential Medicine 2022 for potential DDI analysis by Micromedex and Drugs.com. From these databases, 488 potential DDIs were identified. There were 271 and 434 DDI pairs based on Micromedex and Drugs.com, respectively. Among these DDIs, 77 pairs were labeled as contraindicated or major by both databases. The most common mechanisms for these serious interactions are cytochrome P450 (CYP) inhibition (45%), CYP induction (19%), and QT interval prolongation (7.8%). Based on Fleiss' kappa (0.073), there was only slight agreement of the DDI severity classifications between these two databases. In conclusion, a large number of potential DDIs were detected among frequently prescribed medications for long COVID. Health care providers should be aware of these DDIs, particularly those that are deemed as contraindicated or major. These DDIs are most likely to cause significant adverse events in patients with long COVID because polypharmacy is common.
Identifiants
pubmed: 37972000
doi: 10.1371/journal.pone.0293866
pii: PONE-D-22-26829
pmc: PMC10653453
doi:
Substances chimiques
Cytochrome P-450 Enzyme System
9035-51-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0293866Informations de copyright
Copyright: © 2023 Meakleartmongkol et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2019 Nov 14;14(11):e0225239
pubmed: 31725785
Clin Pharmacol Ther. 2020 Aug;108(2):242-247
pubmed: 32246834
HIV Med. 2007 Mar;8(2):131-4
pubmed: 17352770
Expert Opin Drug Saf. 2010 Sep;9(5):723-42
pubmed: 20345324
Pharmaceutics. 2011 Nov 18;3(4):865-913
pubmed: 24309312
J Infect Dis. 2022 Nov 1;226(9):1593-1607
pubmed: 35429399
J Clin Pharm Ther. 2017 Apr;42(2):135-146
pubmed: 28177134
Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):561-80
pubmed: 24521092
Front Pharmacol. 2021 Mar 12;11:554961
pubmed: 33776749
Eur J Clin Pharmacol. 2009 Jul;65(7):743-5
pubmed: 19399485
Sci Rep. 2021 Mar 17;11(1):6089
pubmed: 33731842
Metab Syndr Relat Disord. 2022 May;20(4):191-198
pubmed: 34995147
Dis Model Mech. 2009 May-Jun;2(5-6):231-7
pubmed: 19407331
Chest. 1991 Feb;99(2):465-71
pubmed: 1824929
Indian J Nephrol. 2016 Sep;26(5):322-328
pubmed: 27795624
J Med Chem. 2016 Jul 28;59(14):6595-628
pubmed: 26878082
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571